Vor Biopharma Inc. (VOR)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitacicept, a dual BAFF/APRIL inhibitor with multiple China approvals. VOR holds $491.5 million in cash, providing runway through early 2029 and enabling Phase 3 clinical trial readouts in gMG and Sjögren's disease before requiring additional capital. Telitacicept's differentiation lies in upstream B-cell pathway inhibition, with promising efficacy signals across gMG, SjD, and IgAN, but faces intense competition and regulatory translation risk.
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vor Biopharma: It's A Game Of Wait And See
Vor Biopharma Inc. has pivoted to immunology, raising over $500m in 2025 to advance telitacicept for U.S. approval. VOR holds $530m cash, extending its runway into 2029, but faces significant dilution risk from outstanding warrants and equity plans. Telitacicept, already approved in China for multiple indications, must now clear pivotal Phase 3 US trials, with data not expected until 2027.
Vor Biopharma (VOR) Upgraded to Buy: Here's Why
Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 107.8% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vor Biopharma Inc. (VOR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vor Biopharma Inc. (VOR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know
Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross
Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Vor Bio price target lowered to $8 from $10 at Oppenheimer
Oppenheimer analyst Matthew Biegler lowered the firm's price target on Vor Bio to $8 from $10 and keeps an Outperform rating on the shares following the Q3 report. The firm cites updated spending estimates based on guidance from management for the target. It acknowledges Vor's "financial overhang," but still views the company as a "deeply discounted innovator in the biotech sector."
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg.
